Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M127,004Revenue (TTM) $M22,474Net Margin (%)33.1Altman Z-Score2.9
Enterprise Value $M125,192EPS (TTM) $9.8Operating Margin %40.7Piotroski F-Score8
P/E(ttm)17.4Beneish M-Score-2.5Pre-tax Margin (%)38.1Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %11.8Quick Ratio3.7Cash flow > EarningsY
Price/Sales5.85-y EBITDA Growth Rate %17.6Current Ratio4.0Lower Leverage y-yY
Price/Free Cash Flow15.9y-y EBITDA Growth Rate %25.1ROA % (ttm)10.2Higher Current Ratio y-yN
Dividend Yield %2.2PEG1.0ROE % (ttm)26.1Less Shares Outstanding y-yY
Payout Ratio %37.0Shares Outstanding M748ROIC % (ttm)27.8Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNMartin Whitman 2016-07-31 Buy 1.85%$144.58 - $172.03
($156.46)
$ 169.678%New holding121,300
AMGNThird Avenue Management 2016-06-30 Buy 0.92%$144.58 - $164.35
($155.39)
$ 169.679%New holding135,642
AMGNJoel Greenblatt 2016-06-30 Add0.3%$144.58 - $164.35
($155.39)
$ 169.679%Add 50.26%485,933
AMGNFirst Eagle Investment 2016-06-30 Reduce-0.11%$144.58 - $164.35
($155.39)
$ 169.679%Reduce -24.17%936,565
AMGNVanguard Health Care Fund 2016-06-30 Reduce-0.02%$144.58 - $164.35
($155.39)
$ 169.679%Reduce -0.98%5,190,355
AMGNKeeley Asset Management Corp 2016-06-30 Buy 0.01%$144.58 - $164.35
($155.39)
$ 169.679%New holding1,325
AMGNDodge & Cox 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 169.679%Reduce -5.28%41,257
AMGNKen Fisher 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 169.679%Reduce -9.87%101,573
AMGNMario Gabelli 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 169.679%Reduce -2.38%36,325
AMGNFirst Eagle Investment 2016-03-31 Add0.11%$140.9 - $162.33
($148.76)
$ 169.6714%Add 28.98%1,235,154
AMGNJoel Greenblatt 2016-03-31 Add0.08%$140.9 - $162.33
($148.76)
$ 169.6714%Add 16.86%323,405
AMGNVanguard Health Care Fund 2016-03-31 Reduce-0.05%$140.9 - $162.33
($148.76)
$ 169.6714%Reduce -2.91%5,241,755
AMGNKen Fisher 2016-03-31 Reduce-0.01%$140.9 - $162.33
($148.76)
$ 169.6714%Reduce -17.38%112,693
AMGNGeorge Soros 2016-03-31 Sold Out -0.01%$140.9 - $162.33
($148.76)
$ 169.6714%Sold Out0
AMGNMario Gabelli 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 169.6714%Reduce -5.02%37,210
AMGNDodge & Cox 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 169.6714%Reduce -6.62%43,557
AMGNRuane Cunniff 2016-03-31 Sold Out $140.9 - $162.33
($148.76)
$ 169.6714%Sold Out0
AMGNJoel Greenblatt 2015-12-31 Reduce-0.18%$141.22 - $164.58
($157.65)
$ 169.678%Reduce -31.85%276,751
AMGNFirst Eagle Investment 2015-12-31 Add0.17%$141.22 - $164.58
($157.65)
$ 169.678%Add 73.61%957,656
AMGNVanguard Health Care Fund 2015-12-31 Reduce-0.05%$141.22 - $164.58
($157.65)
$ 169.678%Reduce -3.25%5,398,985
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Such Annette LouiseVP, Finance and CAO 2016-08-02Sell3,000$174.59-1.7view
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.1211.36view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.998.63view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.219.17view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.4817.17view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.8411.56view
Hassan FredDirector 2015-08-19Buy3,010$166.633view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-4.86view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.069.28view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.878.72view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 
    Third Avenue Fund Comments on Amgen Sep 14 2016 
    Third Avenue Fund Comments on Amgen Sep 14 2016 
    Third Avenue Value Fund 3rd Quarter Letter Sep 14 2016 
    Lee Ainslie Invests in Apple, American Airlines Sep 12 2016 
    AbbVie: Investors Apprehensive About Humira Sep 06 2016 
    21 Best Undervalued Stocks of the Week Aug 30 2016 
    Martin Whitman’s Third Avenue Management Purchases 8 Stocks Aug 12 2016 
    Healthcare Dividend Growth Stocks: Part 1 Aug 12 2016 
    Healthcare Dividend Growth Stocks: Part 1 Aug 04 2016 

    More From Other Websites
    Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016
    Amgen's Osteoporosis Drug Crosses a Hurdle (AMGN) Sep 27 2016
    Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade Sep 27 2016
    Why Wells Fargo, Gilead, Newfield, Amgen, and Chesapeake Energy Are Trending Sep 27 2016
    Stocks Extend Gains; Facebook Up On Positive Analyst Chatter Sep 27 2016
    Stocks Up After 1st Presidential Debate; Why Tesla Looks Healthiest In Weeks Sep 27 2016
    The Drug Price Increase Debate: Separating The Winners From The Losers Sep 27 2016
    Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design Sep 27 2016
    Amgen's multiple myeloma drug falls short in new-patient study Sep 27 2016
    Amgen: The Blame Game Sep 27 2016
    Amgen/UCB's BLA for Osteoporosis Drug Accepted in the U.S. Sep 27 2016
    Amgen Inc Investor Conference Call to discuss CLARION Data scheduled for 8:30 am ET today Sep 27 2016
    Biosimilars in Limelight on FDA Approval of Amgen Drug Sep 27 2016
    Short Sellers Increase Bets in Major Biotechs Sep 27 2016
    Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients Sep 27 2016
    Amgen's multiple myeloma drug falls short in late stage study Sep 27 2016
    Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly... Sep 27 2016
    4:14 am Amgen reports Phase 3 KYPROLIS; trial did not meet the primary endpoint Sep 27 2016
    Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly... Sep 27 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)